Evolus Inc. announces that a peer-reviewed, post-hoc analysis published in Aesthetic Surgery Journal showed with high consistency that males treated with Jeuveau (prabotulinumtoxinA-xvfs), the company’s neurotoxin product, had higher responder rates than those treated with Botox (onabotulinumtoxinA) across nearly all time points examined.
The post-hoc analyses were performed on a subpopulation of male patients treated for glabellar lines with either a single dose of 20U Jeuveau or Botoxin a double-blind, randomized phase III clinical trial. The analysis included a total of 56 males, with 25 receiving Jeuveau and 31 receiving Botox.
Compared with Botox-treated males, percentages of males treated with Jeuveau who had a ≥1 point improvement on the glabellar line severity scale at maximum frown were higher at all post-baseline time points by an average of 10.1% across nearly all visits, though with the small sample size, results did not reach statistical significance.
Similar trends were observed for efficacy endpoints based on the global aesthetic improvement and subject satisfaction scales, and no serious adverse events were related to either toxin.
“Published comparative clinical data focused on treating male patients with botulinum toxins is very limited,” says Rui Avelar, MD, chief medical officer and head of research and development at Evolus. “This post hoc analysis provides for a head-to-head comparison in a more difficult to treat patient population and may help evaluate the relative potency of Jeuveau and Botox.”
“Male patients can be challenging to treat as their frown muscles, the corrugators and the procerus, tend to have more muscle mass than women,” says Nowell Solish, MD, FRCP, cosmetic dermatologist and principal investigator. “The ad hoc analysis demonstrates that Jeuveau is an excellent option for male patients as seen in their high response rates. This is encouraging news for the many male patients who are embracing botulinum aesthetic treatments.”
Botulinum toxin injections continue to be the most common non-surgical cosmetic procedure performed in both males and females and are rapidly increasing in popularity among males. According to the American Society of Plastic Surgeons, more than 265,000 botulinum toxin treatments were administered to men in 2020 alone.
“Cosmetic toxin injections in men have increased in popularity by an astonishing 380% between 2000 and 2018,” says David Moatazedi, president and CEO of Evolus. “While we remain focused on the millennial demographic, it is important for us to understand how the underpenetrated and growing male patient population responds to treatment. We are excited to see the favorable results in this analysis, which further validate our ongoing clinical study examining an ‘extra-strength’ dosing option of Jeuveau to provide more options for treating diverse patient populations.”
Jeuveauis used for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) in adults below 65 years of age. Since the launch of Jeuveau, an estimated 2 million treatments have been administered by more than 8,100 purchasing customers nationwide.
The product is approved for sale in the United States under the brand name Jeuveau® and in Canada under the brand name Nuceiva®.